Cristiano Capurso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2946614/publications.pdf

Version: 2024-02-01

70961 79541 5,747 130 41 73 citations h-index g-index papers 130 130 130 7364 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Whole-Grain Intake in the Mediterranean Diet and a Low Protein to Carbohydrates Ratio Can Help to Reduce Mortality from Cardiovascular Disease, Slow Down the Progression of Aging, and to Improve Lifespan: A Review. Nutrients, 2021, 13, 2540.	1.7	18
2	The mediterranean way. Should elderly people eat leafy vegetables and beetroot to lower high blood pressure?. Aging Clinical and Experimental Research, 2021, 33, 2613-2621.	1.4	0
3	The Mediterranean diet: a pathway to successful aging. Aging Clinical and Experimental Research, 2020, 32, 1187-1188.	1.4	11
4	Hemostasis and Thrombosis. , 2020, , 361-369.		1
5	The Mediterranean way: why elderly people should eat wholewheat sourdough bread—a little known component of the Mediterranean diet and healthy food for elderly adults. Aging Clinical and Experimental Research, 2020, 32, 1-5.	1.4	38
6	The Mediterranean Diet Slows Down the Progression of Aging and Helps to Prevent the Onset of Frailty: A Narrative Review. Nutrients, 2020, 12, 35.	1.7	72
7	Adherence to Mediterranean Diet, Malnutrition, Length of Stay and Mortality in Elderly Patients Hospitalized in Internal Medicine Wards. Nutrients, 2019, 11, 790.	1.7	15
8	The Impact of theÂMediterranean Diet on Aging, Frailty, and Longevity. Practical Issues in Geriatrics, 2018, , 417-439.	0.3	0
9	Extra-virgin Olive Oil, the Mediterranean Diet, and Neurodegenerative Diseases. Practical Issues in Geriatrics, 2018, , 81-95.	0.3	O
10	Cereals. Practical Issues in Geriatrics, 2018, , 139-172.	0.3	3
11	The Mediterranean Diet Reduces the Risk and Mortality of the Prostate Cancer: A Narrative Review. Frontiers in Nutrition, 2017, 4, 38.	1.6	47
12	Vascular effects of the Mediterranean dietâ€"Part II: Role of omega-3 fatty acids and olive oil	1.0	64
	polyphenols. Vascular Pharmacology, 2014, 63, 127-134.	1.0	04
13	Vascular effects of the Mediterranean diet Part I: Anti-hypertensive and anti-thrombotic effects. Vascular Pharmacology, 2014, 63, 118-126.	1.0	27
13	Vascular effects of the Mediterranean diet Part I: Anti-hypertensive and anti-thrombotic effects.		
	Vascular effects of the Mediterranean diet Part I: Anti-hypertensive and anti-thrombotic effects. Vascular Pharmacology, 2014, 63, 118-126. From excess adiposity to insulin resistance: The role of free fatty acids. Vascular Pharmacology, 2012,	1.0	27
14	Vascular effects of the Mediterranean diet Part I: Anti-hypertensive and anti-thrombotic effects. Vascular Pharmacology, 2014, 63, 118-126. From excess adiposity to insulin resistance: The role of free fatty acids. Vascular Pharmacology, 2012, 57, 91-97. Has dysregulated interleukin-6 gene a role in the development of Alzheimer's disease?. Neuroscience	1.0	27
14 15	Vascular effects of the Mediterranean diet Part I: Anti-hypertensive and anti-thrombotic effects. Vascular Pharmacology, 2014, 63, 118-126. From excess adiposity to insulin resistance: The role of free fatty acids. Vascular Pharmacology, 2012, 57, 91-97. Has dysregulated interleukin-6 gene a role in the development of Alzheimer's disease?. Neuroscience Letters, 2011, 504, 1-3. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal	1.0	238

#	Article	IF	CITATIONS
19	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 21, 691-724.	1.2	139
20	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	1.2	78
21	EFFECT OF DONEPEZIL ON THE CONTINUUM OF DEPRESSIVE SYMPTOMS, MILD COGNITIVE IMPAIRMENT, AND PROGRESSION TO DEMENTIA. Journal of the American Geriatrics Society, 2010, 58, 389-390.	1.3	6
22	Polymorphism C in the Serotonin Transporter Gene in Depression-Free Elderly Patients with Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2010, 29, 424-431.	0.7	6
23	Dietary Patterns and Protection Against Alzheimer Disease and Cognitive Decline. Archives of Neurology, 2010, 67, 1285.	4.9	5
24	Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 433-440.	0.9	100
25	Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid. Current Alzheimer Research, 2010, 7, 40-55.	0.7	109
26	Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?. American Journal of Geriatric Psychiatry, 2010, 18, 98-116.	0.6	502
27	Polymorphisms in Glutathione <i>S</i> -Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease. Rejuvenation Research, 2010, 13, 645-652.	0.9	23
28	Interleukin 6–174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 177-182.	2.5	27
29	Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms. Ageing Research Reviews, 2010, 9, 184-199.	5.0	112
30	Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Research Reviews, 2010, 9, 399-417.	5.0	292
31	REVIEW: γâ€Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. CNS Neuroscience and Therapeutics, 2010, 16, 272-284.	1.9	63
32	Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?. Journal of Alzheimer's Disease, 2010, 21, 57-63.	1.2	69
33	Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	1.2	42
34	Cognitive behavioural group therapy in mild cognitive impairment: Intervention with a cognitive or behavioural/psychological focus?. Journal of Rehabilitation Medicine, 2009, 41, 293-294.	0.8	1
35	Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review. Scientific World Journal, The, 2009, 9, 373-389.	0.8	24
36	Dietary Fatty Acids and Predementia Syndromes. Scientific World Journal, The, 2009, 9, 792-810.	0.8	10

3

#	Article	IF	Citations
37	All-Cause Mortality and Competing Risks of Fatal and Nonfatal Vascular Events in the Italian Longitudinal Study on Aging: Impact of Lipoprotein(a). Rejuvenation Research, 2009, 12, 395-402.	0.9	4
38	Mediterranean Dietary Pattern, Mild Cognitive Impairment, and Progression to Dementia. Archives of Neurology, 2009, 66, 910.	4.9	5
39	Moderate Alcohol Consumption, Apolipoprotein E, and Neuroprotection. Archives of Neurology, 2009, 66, 538.	4.9	17
40	APOLIPOPROTEIN E, DEMENTIA, AND HUMAN LONGEVITY. Journal of the American Geriatrics Society, 2009, 57, 740-742.	1.3	7
41	POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENT–NO DEMENTIA. Journal of the American Geriatrics Society, 2009, 57, 943-944.	1.3	3
42	Wholeâ€Diet Approach: Working on a Criterion Validity for Ageâ€Related Cognitive Decline and Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2009, 57, 1944-1946.	1.3	13
43	Higher total cholesterol, cognitive decline, and dementia. Neurobiology of Aging, 2009, 30, 546-548.	1.5	18
44	Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1518-1520.	1.5	11
45	Effect of interleukin-6 polymorphisms on human longevity: A systematic review and meta-analysis. Ageing Research Reviews, 2009, 8, 36-42.	5.0	93
46	Disease-Modifying Approach to the Treatment of Alzheimer's Disease. Drugs and Aging, 2009, 26, 537-555.	1.3	80
47	Beyond the neurotransmitter-focused approach in treating Alzheimer's Disease: drugs targeting β-amyloid and tau protein. Aging Clinical and Experimental Research, 2009, 21, 386-406.	1.4	47
48	N-3 polyunsaturated fatty acids and statins in heart failure. Lancet, The, 2009, 373, 380.	6.3	0
49	Temporal Relationship between Depressive Symptoms and Cognitive Impairment: The Italian Longitudinal Study on Aging. Journal of Alzheimer's Disease, 2009, 17, 899-911.	1.2	49
50	Possible Role of S-Adenosylmethionine, S-Adenosylhomocysteine, and Polyunsaturated Fatty Acids in Predementia Syndromes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 467-470.	1.2	23
51	Alcohol Drinking, Cognitive Functions in Older Age, Predementia, and Dementia Syndromes. Journal of Alzheimer's Disease, 2009, 17, 7-31.	1.2	98
52	Vascular risk factors, alcohol intake, and cognitive decline. Journal of Nutrition, Health and Aging, 2008, 12, 376-381.	1.5	29
53	Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment. Journal of Nutrition, Health and Aging, 2008, 12, 382-386.	1.5	46
54	Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging. International Journal of Geriatric Psychiatry, 2008, 23, 726-734.	1.3	62

#	Article	IF	CITATIONS
55	BEYOND CORONARY ARTERY DISEASE: ROSUVASTATIN IN OLDER PATIENTS WITH ISCHEMIC SYSTOLIC HEART FAILURE. Journal of the American Geriatrics Society, 2008, 56, 1366-1367.	1.3	2
56	MILD COGNITIVE IMPAIRMENT: DEMENTIA RISK FACTOR OR HIGHâ€RISK STATE FOR PROGRESSION TO DEMENTIA?. Journal of the American Geriatrics Society, 2008, 56, 1367-1369.	1.3	3
57	Lifestyle-related factors in predementia and dementia syndromes. Expert Review of Neurotherapeutics, 2008, 8, 133-158.	1.4	129
58	Depressive Symptoms, Vascular Risk Factors and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2008, 25, 336-346.	0.7	38
59	Short arm of chromosome 11 and sporadic Alzheimer's disease: Catalase and cathepsin D gene polymorphisms. Neuroscience Letters, 2008, 432, 237-242.	1.0	18
60	S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in predementia syndromes and Alzheimer's disease. Neurobiology of Aging, 2008, 29, 478-480.	1.5	4
61	Hypertension and Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 992.	4.9	6
62	Alcohol Use, Thiamine Deficiency, and Cognitive Impairment. JAMA - Journal of the American Medical Association, 2008, 299, 2853.	3.8	12
63	EFFECT OF A CLINICAL STROKE ON THE RISK OF DEMENTIA IN A PROSPECTIVE COHORT. Neurology, 2007, 68, 1748-1749.	1.5	0
64	Mild cognitive impairment: Risk of Alzheimer disease and rate of cognitive decline. Neurology, 2007, 68, 964-965.	1.5	8
65	Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology, 2007, 68, 1238-1239.	1.5	1
66	Progression to Dementia in Probable and Possible Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1209.	4.9	2
67	Alcohol consumption, mild cognitive impairment, and progression to dementia. Neurology, 2007, 68, 1790-1799.	1.5	133
68	Whole-Diet Approach, Mediterranean Diet, and Alzheimer Disease. Archives of Neurology, 2007, 64, 606.	4.9	6
69	Apolipoprotein E Genotypes in Hospitalized Elderly Patients with Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2007, 23, 327-333.	0.7	26
70	Incident Occurrence of Depressive Symptoms among Patients with Mild Cognitive Impairment – The Italian Longitudinal Study on Aging. Dementia and Geriatric Cognitive Disorders, 2007, 24, 55-64.	0.7	66
71	Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia. Neurobiology of Aging, 2007, 28, 1631-1632.	1.5	23
72	Lipoproteins, Vascular-Related Genetic Factors, and Human Longevity. Rejuvenation Research, 2007, 10, 441-458.	0.9	25

#	Article	IF	CITATIONS
73	Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages. Atherosclerosis, 2007, 193, 455-457.	0.4	6
74	Possible Role of Unsaturated Fatty Acids in a 14-Day Healthy Longevity Lifestyle Program. American Journal of Geriatric Psychiatry, 2007, 15, 266.	0.6	4
75	TOTAL CHOLESTEROL LEVELS AND THE RISK OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society, 2007, 55, 133-135.	1.3	15
76	DIETARY POLYUNSATURATED FATTY ACID SUPPLEMENTATION, PREDEMENTIA SYNDROMES, AND ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society, 2007, 55, 469-470.	1.3	9
77	CHANGE OF DIAGNOSES IN PROBABLE AND POSSIBLE MILD COGNITIVE IMPAIRMENT: THE ITALIAN LONGITUDINAL STUDY ON AGING. Journal of the American Geriatrics Society, 2007, 55, 1480-1482.	1.3	2
78	LIFESTYLEâ€RELATED FACTORS, ALCOHOL CONSUMPTION, AND MILD COGNITIVE IMPAIRMENT. Journal of the American Geriatrics Society, 2007, 55, 1679-1681.	1.3	11
79	Interleukin 6 Variable Number of Tandem Repeats (VNTR) Gene Polymorphism in Centenarians. Annals of Human Genetics, 2007, 71, 843-848.	0.3	13
80	Mediterranean diet, mild cognitive impairment, and Alzheimer's disease. Experimental Gerontology, 2007, 42, 6-7.	1.2	22
81	Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. Aging Clinical and Experimental Research, 2006, 18, 144-148.	1.4	17
82	Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. Atherosclerosis, 2006, 188, 455-461.	0.4	42
83	Circulating biomarkers of cognitive decline and dementia. Clinica Chimica Acta, 2006, 364, 91-112.	0.5	124
84	Nutritional factors, cognitive decline, and dementia. Brain Research Bulletin, 2006, 69, 1-19.	1.4	83
85	Cognitive frailty: Predementia syndrome and vascular risk factors. Neurobiology of Aging, 2006, 27, 933-940.	1.5	140
86	Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1537-1553.	1.5	22
87	Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8.5-year follow-up of the Italian Longitudinal Study on Aging. Neurobiology of Aging, 2006, 27, 1694-1704.	1.5	222
88	Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia. Journal of Alzheimer's Disease, 2006, 10, 303-330.	1.2	44
89	Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism. Vascular Disease Prevention, 2006, 3, 235-245.	0.2	O
90	PREVALENCE RATES OF MILD COGNITIVE IMPAIRMENT SUBTYPES AND PROGRESSION TO DEMENTIA. Journal of the American Geriatrics Society, 2006, 54, 1474-1475.	1.3	3

#	Article	IF	Citations
91	DIET, CHOLESTEROL METABOLISM, AND ALZHEIMER'S DISEASE: APOLIPOPROTEIN E AS A POSSIBLE LINK?. Journal of the American Geriatrics Society, 2006, 54, 1963-1965.	1.3	9
92	WHOLE-DIET APPROACH AND RISK OF CHRONIC DISEASE: LIMITS AND ADVANTAGES. Journal of the American Geriatrics Society, 2006, 54, 1800-1802.	1.3	19
93	Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging. Experimental Gerontology, 2006, 41, 619-627.	1.2	75
94	Serum total cholesterol as a biomarker for Alzheimer's disease: Mid-life or late-life determinations?. Experimental Gerontology, 2006, 41, 805-806.	1.2	14
95	Cardiovascular Factors and Cognitive Impairment: A Role for Unsaturated Fatty Acids and Mediterranean Diet?. American Journal of Cardiology, 2006, 98, 1120-1121.	0.7	7
96	Lipid metabolism in cognitive decline and dementia. Brain Research Reviews, 2006, 51, 275-292.	9.1	165
97	Candidate genes for late-onset Alzheimer's disease: Focus on chromosome 12. Mechanisms of Ageing and Development, 2006, 127, 36-47.	2.2	16
98	Adherence to a Mediterranean dietary pattern and risk of Alzheimer's disease. Annals of Neurology, 2006, 60, 620-620.	2.8	13
99	Low incidence for predementia and dementia syndromes in a brain imaging study. Annals of Neurology, 2006, 60, 619-619.	2.8	0
100	Stroke and Memory Decline: A Question of Degenerative or Vascular Origin. Archives of Neurology, 2006, 63, 1347.	4.9	1
101	Dietary fatty acids intake: possible role in cognitive decline and dementia. Experimental Gerontology, 2005, 40, 257-270.	1.2	113
102	Unsaturated fatty acids intake and all-causes mortality: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. Experimental Gerontology, 2005, 40, 335-343.	1.2	33
103	Polymorphisms in the Oxidized Low-Density Lipoprotein Receptor-1 Gene and Risk of Alzheimer's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 280-284.	1.7	20
104	Molecular Determinants of Human Longevity. Advances in Clinical Chemistry, 2005, 39, 185-210.	1.8	1
105	The Cathepsin D Gene Exon 2 (C224T) Polymorphism and Sporadic Alzheimer's Disease in European Populations. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 991-996.	1.7	14
106	Current Epidemiology of Mild Cognitive Impairment and Other Predementia Syndromes. American Journal of Geriatric Psychiatry, 2005, 13, 633-644.	0.6	171
107	Current epidemiology of mild cognitive impairment and other predementia syndromes. American Journal of Geriatric Psychiatry, 2005, 13, 633-44.	0.6	109
108	Mediterranean diet and cognitive decline. Public Health Nutrition, 2004, 7, 959-963.	1.1	173

#	Article	IF	CITATIONS
109	Vascular genetic factors and human longevity. Mechanisms of Ageing and Development, 2004, 125, 169-178.	2.2	37
110	Interleukin 6 â°'174 G/C promoter gene polymorphism in centenarians: no evidence of association with human longevity or interaction with apolipoprotein E alleles. Experimental Gerontology, 2004, 39, 1109-1114.	1.2	35
111	Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Experimental Gerontology, 2004, 39, 1567-1573.	1.2	63
112	Vascular risk and genetics of sporadic late-onset Alzheimer's disease. Journal of Neural Transmission, 2004, 111, 69-89.	1.4	60
113	Regional European differences in allele and genotype frequencies of low density lipoprotein receptor-related protein 1 polymorphism in Alzheimer's disease. American Journal of Medical Genetics Part A, 2004, 126B, 69-73.	2.4	19
114	Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: Different allele frequencies between the North and South of Europe. Experimental Gerontology, 2003, 38, 1015-1020.	1.2	66
115	Shifts in angiotensin I converting enzyme insertion allele frequency across Europe: implications for Alzheimer's disease risk. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1159-1161.	0.9	29
116	Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. NeuroReport, 2003, 14, 605-608.	0.6	52
117	Semantic Dementia. American Journal of Geriatric Psychiatry, 2003, 11, 695-696.	0.6	0
118	Semantic Dementia: Neuropsychological and Behavioral Patterns in Relation to Hemispheric Asymmetries. American Journal of Geriatric Psychiatry, 2003, 11, 695-696.	0.6	2
119	F175S Change and a Novel Polymorphism in Presenilin-1 Gene in Late-Onset Familial Alzheimer's Disease. European Neurology, 2002, 47, 209-213.	0.6	10
120	Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 732-736.	0.9	81
121	Selective Attention Skills in Differentiating between Alzheimer's Disease and Normal Aging. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 99-109.	1.2	24
122	Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients ≥65 years of age (The Italian Longitudinal Study on Aging). American Journal of Cardiology, 2002, 89, 825-829.	0.7	37
123	Lipoprotein(a) in the elderly: beyond atherosclerosis. Archives of Gerontology and Geriatrics, 2002, 35, 337-343.	1.4	0
124	Serum apoliprotein E levels in alzheimer's disease and extreme longevity. Archives of Gerontology and Geriatrics, 2002, 35, 345-352.	1.4	5
125	Lack of association between ace polymorphism and Alzheimer's disease in southern Italy. Archives of Gerontology and Geriatrics, 2002, 35, 239-245.	1.4	8
126	Apolipoprotein and antiotensin converting enzyme genes: regional differences and extreme longevity in Europe. Archives of Gerontology and Geriatrics, 2002, 35, 247-251.	1.4	4

#	ARTICLE	IF	CITATIONS
127	Impact of decreased frequency of apolipoprotein E $\hat{l}\mu 4$ allele on Alzheimer's disease in Southern Italy. Archives of Gerontology and Geriatrics, 2001, 33, 299-306.	1.4	1
128	Analysis of individual items of mini-mental state examination in discrimination between normal and demented subjects. Archives of Gerontology and Geriatrics, 2001, 33, 357-362.	1.4	8
129	Apolipoprotein E in Southern Italy: protective effect of ε2 allele in early- and late-onset sporadic Alzheimer's disease. Neuroscience Letters, 2000, 292, 79-82.	1.0	39
130	Decreased frequency of apolipoprotein E $\hat{l}\mu4$ allele from Northern to Southern Europe in Alzheimer's disease patients and centenarians. Neuroscience Letters, 1999, 277, 53-56.	1.0	75